Active Biotech wins European regulatory approval to resume tasquinimod myelofibrosis trial enrollment

• Active Biotech secured European regulatory clearance on May 13 to restart enrollment in the HOVON 172 tasquinimod trial in myelofibrosis.
• The study runs with Oncode and HOVON.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Active Biotech AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.